European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …
inhibitors, mandate regular updating of concepts and management. A European …
[HTML][HTML] European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A Hochhaus, M Baccarani, RT Silver, C Schiffer… - Leukemia, 2020 - nature.com
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …
[HTML][HTML] Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology consensus statement and …
The rate of detection of thyroid nodules and carcinomas has increased with the widespread
use of ultrasonography (US), which is the mainstay for the detection and risk stratification of …
use of ultrasonography (US), which is the mainstay for the detection and risk stratification of …
[HTML][HTML] Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G Saglio, DW Kim, S Issaragrisil… - … England Journal of …, 2010 - Mass Medical Soc
Background Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in …
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
SC Kim, DW Kim, YH Shim, JS Bang, HS Oh… - Journal of controlled …, 2001 - Elsevier
Although the current clinical formulation of paclitaxel (Taxol®) has a promising clinical
activity against a wide variety of tumors, it has significant toxic side effects, some of which …
activity against a wide variety of tumors, it has significant toxic side effects, some of which …
Evidence for several waves of global transmission in the seventh cholera pandemic
Vibrio cholerae is a globally important pathogen that is endemic in many areas of the world
and causes 3–5 million reported cases of cholera every year. Historically, there have been …
and causes 3–5 million reported cases of cholera every year. Historically, there have been …
[HTML][HTML] Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations
The detection of thyroid nodules has become more common with the widespread use of
ultrasonography (US). US is the mainstay for detecting and making the differential diagnosis …
ultrasonography (US). US is the mainstay for detecting and making the differential diagnosis …
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
HM Kantarjian, NP Shah, JE Cortes… - Blood, The Journal …, 2012 - ashpublications.org
Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 …
[HTML][HTML] PKC-θ knockout mice are protected from fat-induced insulin resistance
JK Kim, JJ Fillmore, MJ Sunshine… - The Journal of …, 2004 - Am Soc Clin Investig
Insulin resistance plays a primary role in the development of type 2 diabetes and may be
related to alterations in fat metabolism. Recent studies have suggested that local …
related to alterations in fat metabolism. Recent studies have suggested that local …
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic …
NP Shah, HM Kantarjian, DW Kim, D Réa… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib against
unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with …
unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy and safety with …